Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Acasti Pharma Inc. | exh_322.htm |
| EX-32.1 - EXHIBIT 32.1 - Acasti Pharma Inc. | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - Acasti Pharma Inc. | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - Acasti Pharma Inc. | exh_311.htm |
| EX-23.2 - EXHIBIT 23.2 - Acasti Pharma Inc. | exh_232.htm |
| EX-23.1 - EXHIBIT 23.1 - Acasti Pharma Inc. | exh_231.htm |
| EX-21.1 - EXHIBIT 21.1 - Acasti Pharma Inc. | exh_211.htm |
| EX-10.3 - EXHIBIT 10.3 - Acasti Pharma Inc. | exh_103.htm |
| EX-10.2 - EXHIBIT 10.2 - Acasti Pharma Inc. | exh_102.htm |
| 10-K - FORM 10-K - Acasti Pharma Inc. | f10k_062620p.htm |
Exhibit 23.3
June 29, 2020
Acasti Pharma Inc.
545 Promenade du Centropolis, Suite 100
Laval, Québec
Canada H7T 0A3
Re: Consent of Dr. André Marette
The Board of Directors of Acasti Pharma Inc.,
I hereby consent to the reference to my name and the inclusion of information, data and statements from the non-clinical studies to determine the effect of CaPre on (i) glucose and insulin metabolism in a prediabetes or type 2 diabetic setting and (ii) hyperlipidemia and hepatic metabolism in a prediabetes or type 2 diabetic setting (the “Studies”), as well as any citation of the Studies, in (i) Acasti Pharma Inc.’s (the “Company”) annual report on Form 10-K (“Annual Report”) dated June 29, 2020 for its fiscal year ended March 31, 2020 and (ii) the Company’s registration statements on Form S-8 (No. 333-191383 and No. 333-227476).
I further hereby consent to the filing of this letter as an exhibit to the Annual Report.
In giving such consent, I do not thereby admit that I come within the category of persons whose consent is required under Section 7 of the U.S. Securities Act of 1933, as amended, or the rules and regulations of the U.S. Securities and Exchange Commission thereunder.
Yours faithfully,
| By: | /s/ André Marette | |
| Name: Dr. André Marette | ||